Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study
Wirksamkeit und Sicherheit von Roxadustat bei Anämie unter Chemotherapie bei Patient:innen mit nichtmyeloiden Malignomen: randomisierte, offene, aktiv kontrollierte Phase-III-Studie
Journal of Clinical Oncology · 10.01.2025 · 43 (2) · 143-153
DOI: 10.1200/jco.23.02742 ↗Auf einen Blick
Bei 159 Patient:innen mit chemotherapieinduzierter Anämie war Roxadustat nicht unterlegen gegenüber rHuEPO-α. Der Hb-Anstieg war in beiden Gruppen ähnlich.
Fragestellung
Ist Roxadustat bei chemotherapieinduzierter Anämie bei Patient:innen mit nichtmyeloiden Malignomen nicht unterlegen gegenüber rHuEPO-α?
Methode
Offene, randomisierte Nichtunterlegenheitsstudie der Phase III an 44 Zentren in China; 159 Patient:innen; Roxadustat oder rHuEPO-α 3-mal wöchentlich für 12 Wochen.
Ergebnisse
Per-Protokoll 140 Teilnehmende: Hb-Anstieg von Baseline bis Wochen 9-13 mit Roxadustat 17,1 (13,58 bis 20,71) g/L und mit rHuEPO-α 15,4 (11,34 bis 19,50) g/L; Differenz 1,7 (–3,39 bis 6,84). Nichtunterlegenheit erreicht.
Schlussfolgerung der Autor:innen
Roxadustat war bei CIA in dieser Population rHuEPO-α nicht unterlegen. Die orale Formulierung könnte die Compliance erhöhen.
Kernaussagen
- Hb-Anstieg unter Roxadustat und rHuEPO-α ähnlich
- Nichtunterlegenheit gegenüber rHuEPO-α gezeigt
- Unerwünschte Ereignisse insgesamt vergleichbar
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2025. Verfasst von Shun Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Anemia, Glycine, Isoquinolines, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE We evaluated the efficacy and safety of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, for chemotherapy-induced anemia (CIA) in patients with nonmyeloid malignancies receiving multicycle treatments of chemotherapy. PATIENTS AND METHODS In this open-label, noninferiority phase III study conducted at 44 sites in China, 159 participants age ≥18 years with CIA nonmyeloid malignancy and CIA were randomly assigned (1:1) to oral roxadustat or subcutaneous recombinant human erythropoietin-α (rHuEPO-α) three times a week for 12 weeks. Roxadustat starting dosages were 100, 120, and 150 mg three times a week for participants weighing 40-60 kg, respectively. rHuEPO-α starting dosage for all participants was 150 IU/kg three times a week. Both roxadustat and rHuEPO-α dosages could be modified. The primary end point was least-squares mean (LSM) change in hemoglobin (Hb) concentration from baseline to the concentration averaged over weeks 9-13. RESULTS Of the 159 participants randomly assigned, 140 were included in the per-protocol set (roxadustat, n = 78; rHuEPO-α, n = 62). The LSM (95% two-sided CI) change from baseline to weeks 9-13 in Hb concentration was 17.1 (13.58 to 20.71) g/L with roxadustat and 15.4 (11.34 to 19.50) g/L with rHuEPO-α (mean difference [95% CI], 1.7 [–3.39 to 6.84]). The lower bound of the one-sided 97.5% CI for the treatment difference (‒3.4 g/L) was greater than the predefined noninferiority margin of ‒6.6 g/L, establishing noninferiority. Noninferiority was supported by five of six key secondary end points. Rates of adverse events were generally comparable between treatments and consistent with previous findings. CONCLUSION Roxadustat was noninferior to rHuEPO-α in treating CIA in participants with nonmyeloid malignancies receiving multicycle treatments of myelosuppressive chemotherapy. The oral formulation of roxadustat may potentially increase compliance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Cancer Hospital, Fudan University, Shanghai, China.
- The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Shandong First Medical University Cancer Hospital, Jinan, China.
- Harbin Medical University Cancer Hospital, Harbin, China.
- Neijiang Second People's Hospital, Neijiang, China.
Zitieren
APA
Lu, S., Wu, J., Jiang, J., Guo, Q., Yu, Y., Liu, Y., Zhang, H., Qian, L., Dai, X., Xie, Y., Fu, T., Lee, T., Lu, Y., Ma, R., & Eisner, M. D. (2025). Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. Journal of Clinical Oncology, 43(2), 143-153. https://doi.org/10.1200/jco.23.02742
Vancouver
Lu S, Wu J, Jiang J, Guo Q, Yu Y, Liu Y, et al. Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study. Journal of Clinical Oncology. 2025;43(2):143-153. doi:10.1200/jco.23.02742
BibTeX
@article{Lu2025,
author = {Lu, Shun and Wu, Jiong and Jiang, Jin and Guo, Qisen and Yu, Yan and Liu, Yu and Zhang, Hua and Qian, Ling and Dai, Xiumei and Xie, Yanyan and Fu, Ting and Lee, Tyson and Lu, Yan and Ma, Rui and Eisner, Mark D},
title = {Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {2},
pages = {143--153},
doi = {10.1200/jco.23.02742}
}
EUVIMED